Po-Lin Tseng
Overview
Explore the profile of Po-Lin Tseng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fang H, Tseng P, Hu T, Wang J, Hung C, Lu S, et al.
Virol J
. 2024 Apr;
21(1):79.
PMID: 38570803
Background: No study has comparing hepatitis B virus (HBV) relapse rates among patients with both cancer and hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) who completed anti-viral prophylaxis...
2.
Lin Y, Chen C, Cheng H, Liu C, Chung S, Hsieh M, et al.
Am J Transl Res
. 2024 Jan;
15(12):6701-6717.
PMID: 38186977
Objective: Ribonuclease P RNA component H1 (RPPH1) is a long non-coding RNA (lncRNA) associated with cancer progression. Higher RPPH1 expression in breast and cervical cancer samples than that in normal...
3.
Yang S, Hu T, Chou Y, Kuo Y, Tsai M, Chang K, et al.
J Infect Public Health
. 2023 Oct;
16(11):1852-1859.
PMID: 37837921
Background: Prophylaxis antiviral therapy is recommended for patients with hepatitis B receiving chemotherapy but the ideal treatment duration after chemotherapy cessation needs more evidence for clarification. Aims: This study aimed...
4.
Huang P, Chiu S, Chang K, Tseng P, Yen Y, Tsai M, et al.
Hepatol Int
. 2021 Apr;
15(2):310-317.
PMID: 33907949
Background And Aims: Tenofovir disoproxil fumarate (TDF) and Entecavir (ETV) are commonly used for patients with chronic hepatitis B (CHB), and renal or bone toxicity are possible concerns. This study...
5.
Hu T, Chiu S, Tseng P, Chen C, Lu S, Wang J, et al.
Aliment Pharmacol Ther
. 2020 Oct;
52(11-12):1695-1706.
PMID: 33111400
Background: Comparative long-term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prevention of disease progression to hepatocellular carcinoma (HCC) among high-risk patients with chronic hepatitis B (CHB)-related compensated...
6.
Tseng P, Chen C, Hu K, Cheng H, Lin Y, Tsai W, et al.
Oncotarget
. 2018 May;
9(27):18949-18969.
PMID: 29721175
Malignant tumors often display an aberrant energy metabolism that relies primarily on glycolysis to produce adenosine triphosphate (ATP) the so-called Warburg effect or aerobic glycolysis. Thus, the elucidation of this...
7.
Kuo M, Tseng P, Chou Y, Chang K, Tsai M, Kuo Y, et al.
J Gastroenterol Hepatol
. 2018 Mar;
33(10):1766-1772.
PMID: 29514418
Background And Aim: This study investigated whether hepatitis B surface antigen (HBsAg) could predict hepatitis B virus (HBV) relapse after cessation of entecavir or tenofovir disoproxil fumarate (TDF) prophylaxis for...
8.
Tseng P, Wu W, Hu T, Chen C, Cheng H, Li C, et al.
Sci Rep
. 2018 Feb;
8(1):3081.
PMID: 29449614
Changes in TCA cycle enzymes or respiratory activity are possible mechanisms of aerobic glycolysis that contributes to tumor progression. To clarify whether the decrease of succinate dehydrogenase B (SDHB) alters...
9.
Chang K, Ye Y, Wu C, Lin M, Tsai M, Tseng P, et al.
J Formos Med Assoc
. 2017 Dec;
117(11):1011-1018.
PMID: 29254684
Background/purpose: Although antiviral therapy reduces development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC), HCC often develops in patients with non-sustained virologic response (non-SVR). We aimed to...
10.
Yen Y, Lin M, Kuo F, Chang K, Tsai M, Tseng P, et al.
Liver Int
. 2017 Nov;
38(6):1064-1073.
PMID: 29164767
Background & Aims: Diabetes mellitus (DM) has been found to be strongly associated with an increased risk of hepatocellular carcinoma (HCC) among chronic hepatitis C (CHC) patients. Several studies have...